Human focal cerebral infarctions induce differential lesional interleukin-16 (IL-16) expression confined to infiltrating granulocytes, CD8+ T-lymphocytes and activated microglia/macrophages.
Focal cerebral ischemia elicits a strong inflammatory response which readily participates in lipid oxygenation, edema formation, apoptotic cell death and tissue remodeling. Within these conditions, cytokines are key players of cell activation and are crucial for delayed mechanisms of ischemic damage. Mature IL-16 is an immunomodulatory cytokine, exerting CD4 dependent and independent effects and is characterized by chemotactic activity, induction of early gene phosphorylation, stimulation of pro-inflammatory IL-1beta, IL-6, TNFalpha expression in monocytic cells and also modulates apoptosis. We have now analyzed expression of IL-16 in 20 brains of patients following focal cerebral infarctions (FCI, n=20). Compared to normal control brains (n=3), IL-16 was expressed by infiltrating immune cells such as neutrophils, CD8+ lymphocytes and activated CD68+ microglia/macrophages accumulating in lesion associated reactive zones and in peri-vascular regions. IL-16+ cells accumulated significantly (P<0.0001) in the necrotic lesion and at bordering peri-lesional areas at day 1-2 reaching maximum levels at day 3-4 (P<0.0001). Also, peri-vascular IL-16+ cells reached maximum levels at day 3-4 (P<0.0001) following infarction and decreased after several weeks. During the early microglial activation period, IL-16+ microglia/macrophages coexpress the activation antigen MRP-8. The accumulation of IL-16+ granulocytes, IL-16+, CD8+ lymphocytes and activated IL-16+, CD68+, CD4- microglia/macrophages, early after infarction suggest a CD4 independent, paracrine role of IL-16 in the postinjury inflammatory response, such as recruitment and activation of immune cells leading to microvessel clustering and blood-brain barrier disturbance resulting in secondary damage.
Institute of Brain Research, University of Tuebingen, Medical School, Calwer Str. 3, D-72076 Tuebingen, Germany. jmschwab@med.uni-tuebingen.de
J M
JM
Schwab
T D
TD
Nguyen
R
R
Meyermann
H J
HJ
Schluesener
D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal; D001812:Blood-Brain Barrier / Q000276:immunology; D002545:Brain Ischemia / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology / Q000378:metabolism*; D002544:Cerebral Infarction / Q000276:immunology*; D004660:Encephalitis / Q000276:immunology; D005260:Female; D006098:Granulocytes / Q000276:immunology / Q000378:metabolism*; D006801:Humans; D019410:Interleukin-16 / Q000096:biosynthesis* / Q000276:immunology; D008198:Lymph Nodes / Q000276:immunology; D008264:Macrophages / Q000276:immunology / Q000378:metabolism; D008297:Male; D017628:Microglia / Q000276:immunology / Q000378:metabolism*; D008875:Middle Aged
D000911:Antibodies, Monoclonal; D019410:Interleukin-16